These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 7517172)

  • 1. Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte.
    Morel P; Dupriez B; Herbrecht R; Bastion Y; Tilly H; Delannoy A; Haioun C; Nouvel C; Bouabdallah K; Baumelou E
    Br J Cancer; 1994 Jul; 70(1):154-9. PubMed ID: 7517172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.
    Coiffier B; Gisselbrecht C; Vose JM; Tilly H; Herbrecht R; Bosly A; Armitage JO
    J Clin Oncol; 1991 Feb; 9(2):211-9. PubMed ID: 1703226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte.
    Diviné M; Lepage E; Brière J; Pautier P; Dupriez B; Lederlin P; Mineur P; Tilly H; Blanc M; Audhuy B; Herbrecht R; Coiffier B; Reyes F
    J Clin Oncol; 1996 Jan; 14(1):240-8. PubMed ID: 8558204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
    Brice P; Cazals D; Mounier N; Verola O; Neidhart-Berard AM; Remenieras L; Deconinck E; Doyen C; Hamelsand J; Molina T; Moulonguet I; Gisselbrecht C
    Leukemia; 1998 Feb; 12(2):213-9. PubMed ID: 9519784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).
    Lepage E; Gisselbrecht C; Haioun C; Sebban C; Tilly H; Bosly A; Morel P; Herbrecht R; Reyes F; Coiffier B
    Ann Oncol; 1993 Sep; 4(8):651-6. PubMed ID: 7694634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. A study of the Groupe d'Etude des Lymphomes Agressifs.
    Salles G; Herbrecht R; Tilly H; Berger F; Brousse N; Gisselbrecht C; Coiffier B
    Am J Med; 1991 Jan; 90(1):77-84. PubMed ID: 1702581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.
    Wendum D; Sebban C; Gaulard P; Coiffier B; Tilly H; Cazals D; Boehn A; Casasnovas RO; Bouabdallah R; Jaubert J; Ferrant A; Diebold J; de Mascarel A; Gisselbrecht C
    J Clin Oncol; 1997 Apr; 15(4):1654-63. PubMed ID: 9193366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    Hermine O; Haioun C; Lepage E; d'Agay MF; Briere J; Lavignac C; Fillet G; Salles G; Marolleau JP; Diebold J; Reyas F; Gaulard P
    Blood; 1996 Jan; 87(1):265-72. PubMed ID: 8547651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
    Haioun C; Lepage E; Gisselbrecht C; Salles G; Coiffier B; Brice P; Bosly A; Morel P; Nouvel C; Tilly H; Lederlin P; Sebban C; Brière J; Gaulard P; Reyes F
    J Clin Oncol; 2000 Aug; 18(16):3025-30. PubMed ID: 10944137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs.
    Besson C; Canioni D; Lepage E; Pol S; Morel P; Lederlin P; Van Hoof A; Tilly H; Gaulard P; Coiffier B; Gisselbrecht C; Brousse N; Reyes F; Hermine O;
    J Clin Oncol; 2006 Feb; 24(6):953-60. PubMed ID: 16418500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives).
    Coiffier B; Brousse N; Peuchmaur M; Berger F; Gisselbrecht C; Bryon PA; Diebold J
    Ann Oncol; 1990; 1(1):45-50. PubMed ID: 1706610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F;
    J Clin Oncol; 2004 Jul; 22(14):2826-34. PubMed ID: 15254050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.
    Haioun C; Lepage E; Gisselbrecht C; Coiffier B; Bosly A; Tilly H; Morel P; Nouvel C; Herbrecht R; D'Agay MF
    J Clin Oncol; 1994 Dec; 12(12):2543-51. PubMed ID: 7527453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study.
    Cazals-Hatem D; Lepage E; Brice P; Ferrant A; d'Agay MF; Baumelou E; Brière J; Blanc M; Gaulard P; Biron P; Schlaifer D; Diebold J; Audouin J
    Am J Surg Pathol; 1996 Jul; 20(7):877-88. PubMed ID: 8669537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma.
    Binn M; Ruskoné-Fourmestraux A; Lepage E; Haioun C; Delmer A; Aegerter P; Lavergne A; Guettier C; Delchier JC
    Ann Oncol; 2003 Dec; 14(12):1751-7. PubMed ID: 14630680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.
    Gisselbrecht C; Haioun C; Lepage E; Bastion Y; Tilly H; Bosly A; Dupriez B; Marit G; Herbrecht R; Deconinck E; Marolleau JP; Yver A; Dabouz-Harrouche F; Coiffier B; Reyes F
    Leuk Lymphoma; 1997 Apr; 25(3-4):289-300. PubMed ID: 9168439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VP-16, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.
    Herbrecht R; Garcia JJ; Bergerat JP; Dufour P; Duclos B; Oberling F
    Cancer Chemother Pharmacol; 1989; 24(5):338-9. PubMed ID: 2474382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
    J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
    Coiffier B; Mounier N; Bologna S; Fermé C; Tilly H; Sonet A; Christian B; Casasnovas O; Jourdan E; Belhadj K; Herbrecht R;
    J Clin Oncol; 2003 Dec; 21(23):4402-6. PubMed ID: 14581437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective.
    Coiffier B; Reyes F;
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 1):7-15. PubMed ID: 15934513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.